Erratum to: Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum (Journal of Neuroscience, (2014), 34, 47, (15767), 10.1523/JNEUROSCI.5456-13.2014);Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum

Journal of Neuroscience

Volumn 34, Issue 24, 2014, Pages 8210-8218

  Pifl, Christian ^a   Rajput, Alex ^b   Reither, Harald ^a   Blesa, Javier ^c   Cavada, Carmen ^d   Obeso, José A ^c   Rajput, Ali H ^b   Hornykiewicz, Oleh ^a  

^a Medical University of Vienna   (Austria)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Dopamine; Parkinson's disease; Striatum; Synaptic vesicles; VMAT2

Indexed keywords

1, 2, 3, 6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DIHYDROTETRABENAZINE; SEROTONIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

AGED; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN TISSUE; MACACA FASCICULARIS; MALE; METABOLITE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON TRANSPORT; PUTAMEN; SYNAPSE VESICLE; VERY ELDERLY;

DOPAMINE; PARKINSON'S DISEASE; STRIATUM; SYNAPTIC VESICLES; VMAT2;

AGED; AGED, 80 AND OVER; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; HOMOVANILLIC ACID; HUMANS; MACACA FASCICULARIS; MALE; MPTP POISONING; PARKINSON DISEASE; SYNAPTIC VESICLES; TETRABENAZINE; TRITIUM; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84902170828     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5456-13.2014     Document Type: Erratum

References (67)

1. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306. CrossRef Medline
2. Bilska A, Dubiel M, Sokołowska-Jezewicz M, Lorenc-Koci E, Włodek L (2007) Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience 146:1758-1771. CrossRef Medline
3. Blesa J, Pifl C, Sánchez-González MA, Juri C, García-Cabezas MA, Adanez R, Iglesias E, Collantes M, Peñuelas I, Sánchez-Hernández JJ, Rodríguez-Oroz MC, Avendaño C, Hornykiewicz O, Cavada C, Obeso JA (2012) The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol Dis 48:79-91. CrossRef Medline
4. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138-8148. CrossRef Medline
5. Caudle WM, Colebrooke RE, Emson PC, Miller GW (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 31:303-308. CrossRef Medline
6. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28: 425-433. CrossRef Medline
7. Colliver TL, Pyott SJ, Achalabun M, Ewing AG (2000) VMAT-mediated changes in quantal size and vesicular volume. J Neurosci 20:5276-5282. Medline
8. Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D (2000) Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A 59:229-234. CrossRef Medline
9. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909. CrossRef Medline
10. Dean ED, Torres GE, Miller GW (2007) Alpha-synuclein interacts with VMAT2 to regulate VMAT2 activity. Toxicol Sci 96:45.
11. Edwards RH (1993) Neural degeneration and the transport of neurotransmitters. Ann Neurol 34:638-645. CrossRef Medline
12. Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system (in German). Klin Wochenschr 38:1236-1239. CrossRef Medline
13. 3H]dopamine accumulation by synaptic vesicles purified from rat striatum: inhibition by thiocyanate ion. Brain Res 516:155-160. CrossRef Medline
14. Eyerman DJ, Yamamoto BK (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 103:1219-1227. CrossRef Medline
15. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271-1283. CrossRef Medline
16. Fonnum F, Mariussen E (2009) Mechanisms involved in the neurotoxic effects of environmental toxicants such as polychlorinated biphenyls and brominated flame retardants. J Neurochem 111:1327-1347. CrossRef Medline
17. Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J Neural Transm 76:155-161. CrossRef Medline
18. Fountaine TM, Venda LL, Warrick N, Christian HC, Brundin P, Channon KM, Wade-Martins R (2008) The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur J Neurosci 28:2459-2473. CrossRef Medline
19. Fuentes P, Paris I, Nassif M, Caviedes P, Segura-Aguilar J (2007) Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigraderived cell line-an experimental cell model for dopamine toxicity studies. Chem Res Toxicol 20:776-783. CrossRef Medline
20. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL (2012) Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol 123:653-669. CrossRef Medline
21. Gibb WR, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54:388-396. CrossRef Medline
22. Glatt C, Almonte M, Taylor T, Edwards RH, Freimer N, Tanner C (2006) Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease. Mov Disord 21:426-427. CrossRef Medline
23. Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem 126:591-603. CrossRef Medline
24. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653. Medline
25. Greenfield JG, Bosanquet FD (1953) The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 16:213-226. CrossRef Medline
26. Gründemann J, Schlaudraff F, Haeckel O, Liss B (2008) Elevated alphasynuclein m RNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 36:e38. CrossRef Medline
27. Guillot TS, Miller GW (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39:149-170. CrossRef Medline
28. Guo JT, Chen AQ, Kong Q, Zhu H, Ma CM, Qin C (2008) Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell Mol Neurobiol 28:35-47. CrossRef Medline
29. Hassler R (1938) The pathology of paralysis agitans and post-encephalitic Parkinson's. J für Psychologie und Neurologie 48:387-426.
30. Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93:1956-1961. CrossRef Medline
31. Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 51:35-42. CrossRef Medline
32. Hornykiewicz O (1963) The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease (in German). Wien Klin Wochenschr 75:309-312. Medline
33. Hornykiewicz O (1964) The role of brain dopamine (3-hydroxytyramine) in parkinsonism. In: Biochemical and neurophysiological correlations of centrally acting drugs (Trabucchi E, Paoletti R, Canal N, eds), pp 57-68. Pergamon, Oxford.
34. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2-S9. CrossRef Medline
35. Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4:966-977. Medline
36. Inamdar AA, Hossain MM, Bernstein AI, Miller GW, Richardson JR, Bennett JW (2013) Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration. Proc Natl Acad Sci U S A 110:19561-19566. CrossRef Medline
37. Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, Parkkinen L, Senior SL, Anwar S, Ryan B, Deltheil T, Kosillo P, Cioroch M, Wagner K, Ansorge O, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Wade-Martins R (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A 110:E4016-E4025. CrossRef Medline
38. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13:24-34. Medline
39. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11:2395-2407. CrossRef Medline
40. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 277:38884-38894. CrossRef Medline
41. Lundblad M, Decressac M, Mattsson B, Björklund A (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 109:3213-3219. CrossRef Medline
42. Millar J, Stamford JA, Kruk ZL, Wightman RM (1985) Electrochemical, pharmacological and electrophysiological evidence of rapid dopamine release and removal in the rat caudate nucleus following electrical stimulation of the median forebrain bundle. Eur J Pharmacol 109:341-348. CrossRef Medline
43. Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429. CrossRef Medline
44. Moriyama Y, Futai M (1990) H(+)-ATPase, a primary pump for accumulation of neurotransmitters, is a major constituent of brain synaptic vesicles. Biochem Biophys Res Commun 173:443-448. CrossRef Medline
45. Mosharov EV, Gong LW, Khanna B, Sulzer D, Lindau M (2003) Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J Neurosci 23:5835-5845. Medline
46. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62:218-229. CrossRef Medline
47. Nelson N, Cidon S, Moriyama Y (1988) Chromaffin granule proton pump. Methods Enzymol 157:619-633. CrossRef Medline
48. Parkinson J (1817) An essay on the shaking palsy. London: Sherwood, Neely, and Jones.
49. Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508. CrossRef Medline
50. Philippu A, Beyer J (1973) Dopamine and noradrenaline transport into subcellular vesicles of the striatum. Naunyn Schmiedebergs Arch Pharmacol 278:387-402. CrossRef Medline
51. Pothos EN, Larsen KE, Krantz DE, Liu Y, Haycock JW, Setlik W, Gershon MD, Edwards RH, Sulzer D (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 20:7297-7306. Medline
52. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142. Medline
53. Rilstone JJ, Alkhater RA, Minassian BA (2013) Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 368:543-550. CrossRef Medline
54. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41:1303-1307. CrossRef Medline
55. Satou T, Anderson AJ, Itoh T, Tamai Y, Hayashi Y, Hashimoto S (2001) Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats. Exp Toxicol Pathol 53:303-308. CrossRef Medline
56. 3H-norepinephrine by storage vesicles prepared from whole rat brain: properties of the uptake system and its inhibition by drugs. Life Sci 21:1075-1085. CrossRef Medline
57. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41:1308-1312. CrossRef Medline
58. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112-2122. CrossRef Medline
59. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A 86:1398-1400. CrossRef Medline
60. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D (2002) Formation of hydrogen peroxide and hydroxyl radicals from Abeta and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32:1076-1083. CrossRef Medline
61. Terland O, Almås B, Flatmark T, Andersson KK, Sørlie M (2006) Oneelectron oxidation of catecholamines generates free radicals with an in vitro toxicity correlating with their lifetime. Free Radic Biol Med 41: 1266-1271. CrossRef Medline
62. Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, Hazama M, Sora I (2000) The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J 14:2459-2465. CrossRef Medline
63. Vergo S, Johansen JL, Leist M, Lotharius J (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 1185:18-32. CrossRef Medline
64. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285-1296. CrossRef Medline
65. Watabe M, Nakaki T (2008) Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol Pharmacol 74:933-940. CrossRef Medline
66. Whittaker VP, Michaelson IA, Kirkland RJ (1964) The separation of synaptic vesicles from nerve-ending particles ("synaptosomes"). Biochem J 90: 293-303. Medline
67. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, Niznik HB, Hornykiewicz O, Pifl C, Kish SJ (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-726. CrossRef Medline